{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T14:51:14Z","timestamp":1787496674026,"version":"build-2736575974"},"reference-count":78,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,12]],"date-time":"2023-02-12T00:00:00Z","timestamp":1676160000000},"content-version":"am","delay-in-days":348,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.msard.2022.103675","type":"journal-article","created":{"date-parts":[[2022,2,7]],"date-time":"2022-02-07T23:59:39Z","timestamp":1644278379000},"page":"103675","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["A comprehensive review of varicella-zoster virus, herpes simplex virus and cryptococcal infections associated with sphingosine-1-phosphate receptor modulators in multiple sclerosis patients"],"prefix":"10.1016","volume":"59","author":[{"given":"Kanika","family":"Sharma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Durgesh","family":"Chaudhary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Beard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samiksha","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Hassan","family":"Khalid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6844-3287","authenticated-orcid":false,"given":"Shitiz","family":"Sriwastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1\u20132","key":"10.1016\/j.msard.2022.103675_bib0001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jns.2013.05.010","article-title":"Pathology and disease mechanisms in different stages of multiple sclerosis","volume":"333","author":"Lassmann","year":"2013","journal-title":"J. Neurol. Sci."},{"issue":"23","key":"10.1016\/j.msard.2022.103675_bib0002","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1056\/NEJMoa1100648","article-title":"Inflammatory cortical demyelination in early multiple sclerosis","volume":"365","author":"Lucchinetti","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.msard.2022.103675_bib0003","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S1474-4422(14)70256-X","article-title":"Pathological mechanisms in progressive multiple sclerosis","volume":"14","author":"Mahad","year":"2015","journal-title":"Lancet Neurol."},{"issue":"5","key":"10.1016\/j.msard.2022.103675_bib0004","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1056\/NEJMoa0907839","article-title":"Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis","volume":"362","author":"Cohen","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"10127","key":"10.1016\/j.msard.2022.103675_bib0005","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/S0140-6736(18)30475-6","article-title":"EXPAND clinical investigators. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study","volume":"391","author":"Kappos","year":"2018","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.msard.2022.103675_bib0006","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/S1474-4422(19)30239-X","article-title":"Cohen JA; SUNBEAM study investigators. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial","volume":"18","author":"Comi","year":"2019","journal-title":"Lancet Neurol."},{"issue":"11","key":"10.1016\/j.msard.2022.103675_bib0007","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S1474-4422(19)30238-8","article-title":"RADIANCE trial investigators. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial","volume":"18","author":"Cohen","year":"2019","journal-title":"Lancet Neurol."},{"issue":"5","key":"10.1016\/j.msard.2022.103675_bib0008","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1001\/jamaneurol.2021.0405","article-title":"Ponesimod compared with teriflunomide in patients with relapsing multiple sclerosis in the active-comparator phase 3 OPTIMUM study: a randomized clinical trial","volume":"78","author":"Kappos","year":"2021","journal-title":"JAMA Neurol."},{"issue":"5","key":"10.1016\/j.msard.2022.103675_bib0009","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1056\/NEJMoa0909494","article-title":"FREEDOMS study group. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis","volume":"362","author":"Kappos","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"8 Suppl 3","key":"10.1016\/j.msard.2022.103675_bib0010","first-page":"S9","article-title":"The neurobiology of sphingosine 1-phosphate signaling and sphingosine 1-phosphate receptor modulators","volume":"76","author":"Soliven","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2022.103675_bib0011","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.3389\/fimmu.2019.01706","article-title":"Sphingosine-1-phosphate and macrophage biology-how the sphinx tames the big eater","volume":"10","author":"Weigert","year":"2019","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.msard.2022.103675_bib0012","doi-asserted-by":"crossref","first-page":"e12836","DOI":"10.1111\/cmi.12836","article-title":"Sphingosine-1-phosphate receptors and innate immunity","volume":"20","author":"Bryan","year":"2018","journal-title":"Cell. Microbiol."},{"issue":"2","key":"10.1016\/j.msard.2022.103675_bib0013","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/WNF.0b013e3181cbf825","article-title":"Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis","volume":"33","author":"Chun","year":"2010","journal-title":"Clin. Neuropharmacol."},{"issue":"3","key":"10.1016\/j.msard.2022.103675_bib0014","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.pharmthera.2005.05.002","article-title":"FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors","volume":"108","year":"2005","journal-title":"Pharmacol. Ther."},{"issue":"7","key":"10.1016\/j.msard.2022.103675_bib0015","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1128\/IAI.00056-15","article-title":"The granuloma response controlling cryptococcosis in mice depends on the sphingosine kinase 1-sphingosine 1-phosphate pathway","volume":"83","author":"Farnoud","year":"2015","journal-title":"Infect. Immun."},{"issue":"4","key":"10.1016\/j.msard.2022.103675_bib0016","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1212\/CON.0000000000000985","article-title":"Neurologic infections in patients on immunomodulatory and immunosuppressive therapies","volume":"27","author":"Anand","year":"2021","journal-title":"Continuum (Minneap Minn)"},{"key":"10.1016\/j.msard.2022.103675_bib0017","article-title":"Progressive multifocal leukoencephalopathy and sphingosine 1-phosphate receptor modulators used in multiple sclerosis: an updated review of literature","author":"Sriwastava","year":"2021","journal-title":"J. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2022.103675_bib0018","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1001\/jamaneurol.2019.3365","article-title":"Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies","volume":"77","author":"Luna","year":"2020","journal-title":"JAMA Neurol."},{"issue":"14","key":"10.1016\/j.msard.2022.103675_bib0019","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1177\/1352458520970841","article-title":"Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS","volume":"26","author":"Walton","year":"2020","journal-title":"Mult. Scler."},{"issue":"3","key":"10.1016\/j.msard.2022.103675_bib0020","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S1474-4422(18)30443-5","article-title":"GBD of Multiple sclerosis collaborators. Global, regional, and national burden of multiple sclerosis 1990-2016: a systematic analysis for the global burden of disease study 2016","volume":"18","author":"Global","year":"2019","journal-title":"Lancet Neurol."},{"issue":"6","key":"10.1016\/j.msard.2022.103675_bib0021","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/ana.20703","article-title":"Diagnostic criteria for multiple sclerosis: 2005 revisions to the \u201cMcDonald criteria","volume":"58","author":"Polman","year":"2005","journal-title":"Ann. Neurol.: Off. J. Am. Neurol. Assoc. Child Neurol. Soc."},{"issue":"6","key":"10.1016\/j.msard.2022.103675_bib0022","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/ana.20703","article-title":"Diagnostic criteria for multiple sclerosis: 2005 revisions to the \"McDonald Criteria\"","volume":"58","author":"Polman","year":"2005","journal-title":"Ann. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2022.103675_bib0023","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."},{"issue":"5","key":"10.1016\/j.msard.2022.103675_bib0024","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1136\/jnnp-2015-310597","article-title":"TRANSFORMS (TRial Assessing injectable interferoN vS. FTY720 Oral in RRMS) Study Group. Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study","volume":"87","author":"Cohen","year":"2016","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"4","key":"10.1016\/j.msard.2022.103675_bib0025","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.msard.2014.03.002","article-title":"Fingolimod in relapsing multiple sclerosis: an integrated analysis of safety findings","volume":"3","author":"Kappos","year":"2014","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"1","key":"10.1016\/j.msard.2022.103675_bib0026","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1001\/jamaneurol.2014.3065","article-title":"Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for management","volume":"72","author":"Arvin","year":"2015","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2022.103675_bib0027","unstructured":"Cryptococcal Meningitis Fingolimod Global Safety Site. https:\/\/www.fingolimodinfo.com\/en\/cryptococcal-meningitis-0. Accessed December 10, 2021."},{"issue":"Suppl 1","key":"10.1016\/j.msard.2022.103675_bib0028","first-page":"337","article-title":"Long-term efficacy and safety of siponimod treatment for up to 5 years in patients with secondary progressive multiple sclerosis: analysis of the EXPAND extension study","volume":"27","author":"Kappos","year":"2020","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2022.103675_bib0029","first-page":"495","article-title":"Bar-or A. Serious or opportunistic infections in phase 3 studies of ozanimod","volume":"26","author":"Hartung","year":"2019","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2022.103675_bib0030","unstructured":"Sheffield J.K., Janjua A., Campagnolo D., Raghupathi K., Agafonova N., Cree B.A.C., Eds.. Incidence and outcomes of varicella zoster virus (VZV) reactivation in the ozanimod phase-3 clinical program (SUNBEAM and RADIANCE) in relapsing multiple sclerosis (RMS) 2018: WILEY 111 RIVER ST, HOBOKEN 07030-5774, NJ US."},{"key":"10.1016\/j.msard.2022.103675_bib0031","article-title":"Low rate of infections with long-term use of ozanimod in relapsing multiple sclerosis trials (1596)","author":"Hartung","year":"2020","journal-title":"AAN Enterp."},{"key":"10.1016\/j.msard.2022.103675_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102844","article-title":"Ozanimod in relapsing multiple sclerosis: pooled safety results from the clinical development program","volume":"51","author":"Selmaj","year":"2021","journal-title":"Mult Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2022.103675_bib0033","doi-asserted-by":"crossref","unstructured":"Patil S.M., Beck P.P., Arora N., Acevedo B.A., Dandachi D. Primary cutaneous cryptococcal infection due to fingolimod - induced lymphopenia with literature review. IDCases. 2020 May 15;21:e00810. doi: 10.1016\/j.idcr.2020.e00810. PMID: 32518753; PMCID: PMC7270602.","DOI":"10.1016\/j.idcr.2020.e00810"},{"issue":"2","key":"10.1016\/j.msard.2022.103675_bib0034","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1177\/1352458516670732","article-title":"Cutaneous cryptococcosis in a patient taking fingolimod for multiple sclerosis: here come the opportunistic infections?","volume":"23","author":"Carpenter","year":"2017","journal-title":"Mult. Scler."},{"issue":"19","key":"10.1016\/j.msard.2022.103675_bib0035","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1212\/WNL.0b013e3182735d24","article-title":"Multiple sclerosis rebound following herpes zoster infection and suspension of fingolimod","volume":"79","author":"Gross","year":"2012","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.msard.2022.103675_bib0036","first-page":"e16444","article-title":"Primary cutaneous cryptococcosis in a patient on fingolimod: a case report","volume":"13","author":"Dahshan","year":"2021","journal-title":"Cureus"},{"key":"10.1016\/j.msard.2022.103675_bib0037","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102021","article-title":"Necrotizing fungal osteomyelitis and fingolimod, 4 years after treatment with fingolimod","volume":"41","author":"Harirchian","year":"2020","journal-title":"Mult Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2022.103675_bib0038","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jns.2019.06.025","article-title":"Varicella-zoster virus vasculopathy in a multiple sclerosis patient on fingolimod","volume":"403","author":"Muccilli","year":"2019","journal-title":"J. Neurol. Sci."},{"issue":"12","key":"10.1016\/j.msard.2022.103675_bib0039","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.jiac.2016.07.011","article-title":"Herpes zoster laryngitis in a patient treated with fingolimod","volume":"22","author":"Hagiya","year":"2016","journal-title":"J. Infect. Chemother."},{"key":"10.1016\/j.msard.2022.103675_bib0040","doi-asserted-by":"crossref","first-page":"e00961","DOI":"10.1016\/j.idcr.2020.e00961","article-title":"Increased risk of disseminated cryptococcal infection in a patient with multiple sclerosis on fingolimod","volume":"22","author":"Kaur","year":"2020","journal-title":"IDCases"},{"issue":"1","key":"10.1016\/j.msard.2022.103675_bib0041","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/s12883-020-01741-0","article-title":"Cryptococcal meningoencephalitis in an IgG2-deficient patient with multiple sclerosis on fingolimod therapy for more than five years - case report","volume":"20","author":"Wienemann","year":"2020","journal-title":"BMC Neurol."},{"key":"10.1016\/j.msard.2022.103675_bib0042","article-title":"Fingolimod related cryptococcal meningitis and immune reconstitution inflammatory syndrome in two patients with multiple sclerosis (P4. 2-011)","author":"Cuascut","year":"2019","journal-title":"AAN Enterp."},{"key":"10.1016\/j.msard.2022.103675_bib0043","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2019.101923","article-title":"Cryptococcus neoformans var grubii meningoencephalitis in a patient on fingolimod for relapsing-remitting multiple sclerosis: case report and review of published cases","volume":"39","author":"Ma","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2022.103675_bib0044","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.clinimag.2018.11.005","article-title":"Cryptococcal meningitis in a multiple sclerosis patient treated with Fingolimod: a case report and review of imaging findings","volume":"54","author":"Chong","year":"2019","journal-title":"Clin. Imaging"},{"key":"10.1016\/j.msard.2022.103675_bib0045","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2017-220026","article-title":"Cryptococcal meningitis causing obstructive hydrocephalus in a patient on fingolimod","author":"Pham","year":"2017","journal-title":"BMJ Case Rep."},{"key":"10.1016\/j.msard.2022.103675_bib0046","article-title":"Refractory cryptococcal meningoencephalitis in a patient with multiple sclerosis treated with fingolimod: a case report","volume":"12","author":"Anene-Maidoh","year":"2017","journal-title":"Interdiscip. Neurosurg."},{"issue":"22","key":"10.1016\/j.msard.2022.103675_bib0047","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.2169\/internalmedicine.55.7255","article-title":"Disseminated cryptococcosis in a 63-year-old patient with multiple sclerosis treated with fingolimod","volume":"55","author":"Seto","year":"2016","journal-title":"Intern. Med."},{"key":"10.1016\/j.msard.2022.103675_bib0048","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.msard.2016.06.007","article-title":"Cryptococcal meningitis after fingolimod discontinuation in a patient with multiple sclerosis","volume":"9","author":"Ward","year":"2016","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"3","key":"10.1016\/j.msard.2022.103675_bib0049","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1001\/jamaneurol.2015.4259","article-title":"Primary cutaneous cryptococcus in a patient with multiple sclerosis treated with fingolimod","volume":"73","author":"Forrestel","year":"2016","journal-title":"JAMA Neurol."},{"issue":"10","key":"10.1016\/j.msard.2022.103675_bib0050","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1001\/jamaneurol.2015.1746","article-title":"Cryptococcal meningoencephalitis in a patient with multiple sclerosis treated with fingolimod","volume":"72","author":"Achtnichts","year":"2015","journal-title":"JAMA Neurol."},{"issue":"11","key":"10.1016\/j.msard.2022.103675_bib0051","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1212\/WNL.0000000000001929","article-title":"Disseminated cryptococcosis in a patient with multiple sclerosis treated with fingolimod","volume":"85","author":"Huang","year":"2015","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.msard.2022.103675_bib0052","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1212\/WNL.0000000000001109","article-title":"VZV encephalitis that developed in an immunized patient during fingolimod therapy","volume":"84","author":"Issa","year":"2015","journal-title":"Neurology"},{"issue":"23","key":"10.1016\/j.msard.2022.103675_bib0053","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1212\/WNL.0000000000001659","article-title":"Reactivation of herpesvirus under fingolimod: a case of severe herpes simplex encephalitis","volume":"84","author":"Pfender","year":"2015","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.msard.2022.103675_bib0054","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1212\/WNL.0b013e31821043b5","article-title":"Primary varicella zoster infection associated with fingolimod treatment","volume":"76","author":"Uccelli","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2022.103675_bib0055","unstructured":"Key Safety Topics -Infections - Cryptococcal Meningitis. Siponimod global safety site. https:\/\/www.siponimodinfo.com\/en\/key-safety-topics\/cm. Accessed November 16, 2021."},{"issue":"19","key":"10.1016\/j.msard.2022.103675_bib0056","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1212\/WNL.0b013e3182735d00","article-title":"Varicella-zoster virus encephalitis and vasculopathy in a patient treated with fingolimod","volume":"79","author":"Ratchford","year":"2012","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.msard.2022.103675_bib0057","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1177\/1352458513500551","article-title":"Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy","volume":"20","author":"Francis","year":"2014","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2022.103675_bib0058","unstructured":"FULL PRESCRIBING INFORMATION ON GILENYA. US Food and Drug Administration. Gilenya (fingolimod) prescribing information. 2016: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/022527s008lbl.pdf."},{"issue":"1","key":"10.1016\/j.msard.2022.103675_bib0059","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.clim.2010.06.005","article-title":"Reconstitution of circulating lymphocyte counts in FTY720-treated MS patients","volume":"137","author":"Johnson","year":"2010","journal-title":"Clin. Immunol."},{"issue":"11","key":"10.1016\/j.msard.2022.103675_bib0060","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.3390\/cells10113177","article-title":"Lymphocyte counts and multiple sclerosis therapeutics: between mechanisms of action and treatment-limiting side effects","volume":"10","author":"Fischer","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.msard.2022.103675_bib0061","unstructured":"SUMMARY OF PRODUCT CHARACTERISTICS PONVORY. 2022 https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ponvory-epar-product-information_en.pdf."},{"key":"10.1016\/j.msard.2022.103675_bib0062","unstructured":"European Medicines Agency. Gilenya (fingolimod) summary of product characteristics. 2015. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/zeposia-epar-product-information_en.pdf."},{"issue":"8","key":"10.1016\/j.msard.2022.103675_bib0063","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1002\/jcph.887","article-title":"Results from the first-in-human study with ozanimod, a novel, selective sphingosine-1-phosphate receptor modulator","volume":"57","author":"Tran","year":"2017","journal-title":"J. Clin. Pharmacol."},{"issue":"7","key":"10.1016\/j.msard.2022.103675_bib0064","doi-asserted-by":"crossref","first-page":"227","DOI":"10.3390\/biomedicines8070227","article-title":"Sphingosine-1-phosphate: its pharmacological regulation and the treatment of multiple sclerosis: a review article","volume":"8","author":"Cohan","year":"2020","journal-title":"Biomedicines"},{"issue":"5","key":"10.1016\/j.msard.2022.103675_bib0065","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1212\/WNL.0b013e3181ebdd64","article-title":"Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis","volume":"75","author":"Mehling","year":"2010","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.msard.2022.103675_bib0066","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1212\/WNL.0b013e31829a3311","article-title":"T-cell response against varicella-zoster virus in fingolimod-treated MS patients","volume":"81","author":"Ricklin","year":"2013","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.msard.2022.103675_bib0067","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1212\/WNL.0000000000001302","article-title":"Randomized trial of vaccination in fingolimod-treated patients with multiple sclerosis","volume":"84","author":"Kappos","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2022.103675_bib0068","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.101963","article-title":"Is antibody titer useful to verify the immunization after VZV vaccine in MS patients treated with Fingolimod? A case series","volume":"40","author":"Signoriello","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"2","key":"10.1016\/j.msard.2022.103675_bib0069","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/ana.22352","article-title":"Antigen-specific adaptive immune responses in fingolimod-treated multiple sclerosis patients","volume":"69","author":"Mehling","year":"2011","journal-title":"Ann. Neurol."},{"issue":"8","key":"10.1016\/j.msard.2022.103675_bib0070","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1080\/17425255.2016.1196188","article-title":"Clinical pharmacology, efficacy, and safety aspects of sphingosine-1-phosphate receptor modulators","volume":"12","author":"Juif","year":"2016","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.msard.2022.103675_bib0071","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s11910-021-01119-w","article-title":"Central nervous system infections in immunocompromised patients","volume":"21","author":"Pruitt","year":"2021","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"10.1016\/j.msard.2022.103675_bib0072","first-page":"261","article-title":"Fingolimod for multiple sclerosis and emerging indications: appropriate patient selection, safety precautions, and special considerations","volume":"12","author":"Ayzenberg","year":"2016","journal-title":"Ther. Clin. Risk Manag."},{"issue":"6","key":"10.1016\/j.msard.2022.103675_bib0073","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s40264-021-01057-z","article-title":"Safety of S1P modulators in patients with immune-mediated diseases: a systematic review and meta-analysis","volume":"44","author":"Lasa","year":"2021","journal-title":"Drug Saf."},{"issue":"6","key":"10.1016\/j.msard.2022.103675_bib0074","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S1474-4422(14)70049-3","article-title":"Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"13","author":"Calabresi","year":"2014","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2022.103675_bib0075","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.msard.2016.07.015","article-title":"Immunologic mechanisms of fingolimod and the role of immunosenescence in the risk of cryptococcal infection: a case report and review of literature","volume":"9","author":"Grebenciucova","year":"2016","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"19","key":"10.1016\/j.msard.2022.103675_bib0076","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1212\/WNL.0000000000001556","article-title":"Kaposi sarcoma in a patient with relapsing-remitting multiple sclerosis receiving fingolimod","volume":"84","author":"Tully","year":"2015","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.msard.2022.103675_bib0077","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1177\/1203475417719043","article-title":"Primary cutaneous histoplasma capsulatum infection in a patient treated with fingolimod: a case report","volume":"21","author":"Veillet-Lemay","year":"2017","journal-title":"J. Cutan. Med. Surg."},{"key":"10.1016\/j.msard.2022.103675_bib0078","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.msard.2017.05.004","article-title":"Cerebral toxoplasmosis in an MS patient receiving Fingolimod","volume":"18","author":"Enriquez-Marulanda","year":"2017","journal-title":"Mult. Scler. Relat. Disord."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034822001900?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034822001900?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:01:49Z","timestamp":1761901309000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034822001900"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":78,"alternative-id":["S2211034822001900"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2022.103675","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A comprehensive review of varicella-zoster virus, herpes simplex virus and cryptococcal infections associated with sphingosine-1-phosphate receptor modulators in multiple sclerosis patients","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2022.103675","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103675"}}